Chemical trapping of ternary complexes of human immunodeficiency virus type 1 integrase, divalent metal, and DNA substrates containing an abasic site. Implications for the role of lysine 136 in DNA binding.

Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol (2005) 1.30

Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27

Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding. J Biol Chem (2007) 1.26

Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J Virol (2001) 1.12

Mapping viral DNA specificity to the central region of integrase by using functional human immunodeficiency virus type 1/visna virus chimeric proteins. J Virol (1998) 1.09

Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res (2006) 1.05

Recent advances in the investigation of curcuminoids. Chin Med (2008) 0.98

Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93

Identification of a nucleotide binding site in HIV-1 integrase. Proc Natl Acad Sci U S A (1998) 0.89

Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase. Virol J (2010) 0.86

HIV-1 Integrase-DNA Recognition Mechanisms. Viruses (2009) 0.84

A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31

Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem (2000) 4.36

Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J (1999) 3.13

Individual donor nucleic acid testing for blood safety against HIV-1 and hepatitis B and C viruses in a tertiary care hospital. Natl Med J India (2013) 2.56

Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol (2000) 2.41

Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34

Topoisomerase I-mediated DNA damage. Adv Cancer Res (2001) 2.16

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med (2001) 2.04

Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol (1999) 1.97

Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res (1989) 1.94

Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem (1999) 1.91

Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A (1993) 1.91

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (1994) 1.79

Eukaryotic DNA topoisomerases I. Biochim Biophys Acta (1995) 1.76

Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75

Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem (1991) 1.74

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res (1989) 1.71

Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol (1998) 1.69

Human mitochondrial topoisomerase I. Proc Natl Acad Sci U S A (2001) 1.67

Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem (1997) 1.63

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62

The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst (1999) 1.61

Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem (1997) 1.55

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res (1990) 1.50

Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol (1994) 1.46

Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res (1997) 1.44

Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis (2001) 1.44

bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res (1993) 1.43

Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res (1989) 1.43

Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem (2000) 1.42

Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry (1986) 1.39

Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res (1995) 1.36

Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res (2001) 1.34

Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34

Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol (1990) 1.32

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 1.31

Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase. Nucleic Acids Res (1994) 1.29

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res (1995) 1.26

Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci U S A (1998) 1.25

Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry (1997) 1.23

Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem (1995) 1.22

Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol (1995) 1.21

Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry (1990) 1.20

Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in Vitro. J Biol Chem (2000) 1.18

DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res (1987) 1.17

Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol (2000) 1.17

Depletion of poly(ADP-ribose) polymerase by antisense RNA expression results in a delay in DNA strand break rejoining. J Biol Chem (1992) 1.17

Coumarin-based inhibitors of HIV integrase. J Med Chem (1997) 1.16

Host site selection for concerted integration by human immunodeficiency virus type-1 virions in vitro. Virology (1997) 1.16

p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene (2006) 1.15

In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol (2001) 1.15

Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer (1999) 1.15

Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res (1991) 1.14

Inhibitors of human immunodeficiency virus integrase. Adv Virus Res (1999) 1.13

Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett (2001) 1.13

Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 1.13

Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem (1999) 1.13

Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate. Proc Natl Acad Sci U S A (1994) 1.13

Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem Pharmacol (1982) 1.12

Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res (1996) 1.12

Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem (1998) 1.12

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11

Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry (1995) 1.08

Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry (1985) 1.08

Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood (1993) 1.08

The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (1995) 1.07

Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res (1995) 1.07

Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia (1997) 1.06

Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A (2000) 1.06

Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry (1985) 1.06

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res (2001) 1.06

Lamin B phosphorylation by protein kinase calpha and proteolysis during apoptosis in human leukemia HL60 cells. J Biol Chem (1998) 1.06

Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res (1986) 1.06

HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem (1997) 1.05

In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res (1997) 1.05

Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res (1993) 1.05

Inhibitors of poly-(adenosine diphosphoribose) synthesis slow the resealing rate of x-ray-induced DNA strand breaks. Biochem Biophys Res Commun (1982) 1.04

Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J Med Chem (1995) 1.04

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol (2006) 1.04

The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem (2000) 1.04

Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res (1987) 1.04

Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res (1996) 1.03

Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J Mol Biol (1993) 1.03

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene (2011) 1.03

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol (1999) 1.03

Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res (1988) 1.03

Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett (2001) 1.02

Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res (2000) 1.01

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A (1999) 1.01